COMPASS THERAPEUTICS INC (CMPX) Stock Price, Quote, News and Overview
NASDAQ:CMPX - Nasdaq - US20454B1044 - Common Stock - Currency: USD
CMPX Quote, Performance and Key Statistics
2.02
+0.02 (+1%)
The current stock price of CMPX is 2.02 USD. In the past month the price increased by 18.82%. In the past year, price increased by 26.25%.
CMPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.69 | 321.39B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 12.96 | 124.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 63.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 36.86B | ||
| ARGX | ARGENX SE - ADR | 95.7 | 34.30B | ||
| ONC | BEIGENE LTD-ADR | 5.61 | 24.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.20B | ||
| NTRA | NATERA INC | N/A | 20.31B | ||
| BIIB | BIOGEN INC | 7.82 | 18.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.15B |
Related stock screener links
About CMPX
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
Company Info
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS US
Employees: 32
Phone: 16175008099
COMPASS THERAPEUTICS INC / CMPX FAQ
What is the stock price of COMPASS THERAPEUTICS INC today?
The current stock price of CMPX is 2.02 USD. The price increased by 1% in the last trading session.
What is the ticker symbol for COMPASS THERAPEUTICS INC stock?
The exchange symbol of COMPASS THERAPEUTICS INC is CMPX and it is listed on the Nasdaq exchange.
On which exchange is CMPX stock listed?
CMPX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COMPASS THERAPEUTICS INC stock?
16 analysts have analysed CMPX and the average price target is 11.93 USD. This implies a price increase of 490.79% is expected in the next year compared to the current price of 2.02. Check the COMPASS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COMPASS THERAPEUTICS INC worth?
COMPASS THERAPEUTICS INC (CMPX) has a market capitalization of 279.33M USD. This makes CMPX a Micro Cap stock.
How many employees does COMPASS THERAPEUTICS INC have?
COMPASS THERAPEUTICS INC (CMPX) currently has 32 employees.
What are the support and resistance levels for COMPASS THERAPEUTICS INC (CMPX) stock?
COMPASS THERAPEUTICS INC (CMPX) has a support level at 2.01 and a resistance level at 2.13. Check the full technical report for a detailed analysis of CMPX support and resistance levels.
Is COMPASS THERAPEUTICS INC (CMPX) expected to grow?
The Revenue of COMPASS THERAPEUTICS INC (CMPX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CMPX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COMPASS THERAPEUTICS INC (CMPX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CMPX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CMPX, evaluating the profitability, health, valuation and growth aspects
- COMPASS THERAPEUTICS INC (CMPX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COMPASS THERAPEUTICS INC (CMPX) Sales and EPS estimates to see what analysts future expectations are.
- COMPASS THERAPEUTICS INC (CMPX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COMPASS THERAPEUTICS INC (CMPX) Insider and Institutional Ownership to learn about the owners and their transactions.
- COMPASS THERAPEUTICS INC (CMPX) Stock Chart to make your own analysis
- COMPASS THERAPEUTICS INC (CMPX) Latest news and press-releases to stay up to date.
Does COMPASS THERAPEUTICS INC (CMPX) stock pay dividends?
CMPX does not pay a dividend.
When does COMPASS THERAPEUTICS INC (CMPX) report earnings?
COMPASS THERAPEUTICS INC (CMPX) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of COMPASS THERAPEUTICS INC (CMPX)?
COMPASS THERAPEUTICS INC (CMPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the Short Interest ratio of COMPASS THERAPEUTICS INC (CMPX) stock?
The outstanding short interest for COMPASS THERAPEUTICS INC (CMPX) is 7.9% of its float. Check the ownership tab for more information on the CMPX short interest.
CMPX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CMPX. When comparing the yearly performance of all stocks, CMPX is a bad performer in the overall market: 66.62% of all stocks are doing better.
CMPX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPX. CMPX has a great financial health rating, but its profitability evaluates not so good.
CMPX Financial Highlights
Over the last trailing twelve months CMPX reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -8.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.17% | ||
| ROE | -39.43% | ||
| Debt/Equity | 0 |
CMPX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to CMPX. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -28.02% and a revenue growth -100% for CMPX